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The transcription factor FOXP3 is essential for the
suppressive function of regulatory T cells that are
required for maintaining self-tolerance. We have
solved the crystal structure of the FOXP3 forkhead
domain as a ternary complex with the DNA-binding
domain of the transcription factor NFAT1 and a
DNAoligonucleotide from the interleukin-2 promoter.
A striking feature of this structure is that FOXP3
forms a domain-swapped dimer that bridges two
molecules of DNA. Structure-guided or autoimmune
disease (IPEX)-associated mutations in the domain-
swap interface diminished dimer formation by the
FOXP3 forkhead domain without compromising
FOXP3 DNA binding. These mutations also elimi-
nated T cell-suppressive activity conferred by
FOXP3, both in vitro and in amurinemodel of autoim-
mune diabetes in vivo. We conclude that FOXP3-
mediated suppressor function requires dimerization
through the forkhead domain and that mutations in
the dimer interface can lead to the systemic autoim-
munity observed in IPEX patients.
INTRODUCTION
FOXP3 is one of four members of the FOXP subfamily of Fork-
head (FOX) transcription factors (Hannenhalli and Kaestner,
2009). FOXP3 is expressed in regulatory T (Treg) cells, a special-
ized subset of CD4+ T cells that suppress immune responses,
particularly those of autoreactive T cells (Chatila, 2009; Fontenot
et al., 2005; Josefowicz and Rudensky, 2009; Shevach, 2009;
Workman et al., 2009; Ziegler, 2006). In humans, inactivating
mutations in FOXP3 result in a severe autoimmune syndrome
termed IPEX (immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked), which manifests in affected male infants as
lymphocyte infiltration and multiorgan inflammation (Bennett
et al., 2001; Brunkow et al., 2001; Wildin et al., 2001). A similarpathology is observed in the naturally occurring mouse mutant
scurfy, which bears a nonsense mutation in the Foxp3 gene
and lacks FOXP3 protein expression (Bennett et al., 2001; Brun-
kow et al., 2001; Wildin et al., 2001). Targeted deletion of Foxp3
in CD4+ T cells of neonatal or adult mice also results in severe
autoimmunity, emphasizing the ongoing importance of Foxp3
for regulatory T cell function (Williams and Rudensky, 2007).
Finally, ectopic expression of FOXP3 in conventional CD4+
T cells confers suppressor function, enabling the transduced
T cells to suppress the proliferation of bystander T cells in vitro
and limit the effector functions of autoreactive T cells in vivo
(Fontenot et al., 2003; Hori et al., 2003). Although numerous
studies have elucidated the conditions and signaling pathways
required for FOXP3 expression, the biochemical mechanisms
by which FOXP3 induces T regulatory functions are still poorly
understood.
Chromatin immunoprecipitation combined with microarray
analyses revealed numerous transcriptional targets of human
and murine FOXP3, including genes whose expression is
upregulated (Cd25, Ctla4, Tnfrsf18 [Gitr]) and repressed (Il2,
Ptpn22) (Marson et al., 2007; Zheng et al., 2007). FOXP3 cooper-
ates with additional transcription factors, such as NFAT1 and
RUNX1, to regulate gene expression (Wu et al., 2006; Kitoh
et al., 2009; Ono et al., 2007; Rudra et al., 2009). Transcriptional
repression by FOXP3 may reflect its ability to recruit histone
deacetylase (HDAC) family members through an N-terminal
repressor domain (Li and Greene, 2007; Li et al., 2007a).
However, the same N-terminal domain is also responsible for
transcriptional activation by FOXP3 (Wu et al., 2006), and the
stimulatory effects of FOXP3 on gene expression cannot be
explained by recruitment of HDAC corepressor complexes
alone.
IPEX is associated with both nonsense and missense muta-
tions in FOXP3 (van der Vliet and Nieuwenhuis, 2007). FOXP3
forms dimers through a leucine zipper (LZ) region implicated in
homo- and hetero-oligomerization (Chae et al., 2006; Li et al.,
2007b; Lopes et al., 2006), and an IPEX deletion mutation
(DE251) in this region is predicted to disrupt oligomerization
(Chae et al., 2006; Li et al., 2007b; Lopes et al., 2006). Because
the forkhead (FKH) DNA-binding domain of FOXP3 (80 amino
acids) is located at theC-terminal end of the protein, all nonsenseImmunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc. 479
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Role of Forkhead Dimerization in FOXP3 Functionmutations compromise FOXP3 DNA binding. The majority of
missense mutations in IPEX localize to the FKH domain of
FOXP3 (Ochs et al., 2007; Torgerson and Ochs, 2007); however,
only a single IPEX mutation, A384T (Bennett et al., 2001; Wildin
et al., 2001), lies within helix H3 in the structural interface that
mediates DNA contact (Wu et al., 2006). Thus, the mechanisms
by which other IPEX mutations in the FKH domain affect FOXP3
function remain to be explored.
To gain structural insights into the mechanisms by which
FOXP3 modulates gene expression and confers suppressor
functions, we solved the crystal structure of the FKH domain of
FOXP3 bound to DNA in conjunction with the DNA-binding
domain of its partner, nuclear factor of activated T cells 1
(NFAT1). A prominent feature we observed was that the FKH
domain of FOXP3 formed a domain-swapped dimer, simulta-
neously engaging and bringing into close proximity two distant
FOXP3 binding sites in DNA. Based on comparison with other
FOX proteins, we introduced structure-guided mutations into
the dimerization interface of the FKH domain; these mutations
did not affect FOXP3 expression or DNA binding, but caused
dysregulated expression of a subset of FOXP3 target genes
and substantially diminished the ability of FOXP3 to confer
suppressive functions on retrovirally transduced T cells in culture
and in mice. Two known IPEX mutations in the domain-swap
interface had similar biological effects. Our data highlight the
importance of dimer formation for transcriptional regulation by
FOXP3 and indicate that two distinct dimer interfaces of
FOXP3, the LZ motif and the domain swap interface in the FKH
domain, are required for FOXP3-mediated induction of T regula-
tory cell function.
RESULTS
Overall Structure of the NFAT1:FOXP3:DNA Complex
We solved a high-resolution crystal structure of a ternary
complex containing the NFAT1 DNA-binding domain (Rel
homology region, RHR) and the FOXP3 FKH domain bound to
DNA (ARRE2 site of the interleukin-2 [IL-2] promoter) (Figure 1A;
Figure S1 available online). The asymmetric unit (Figure S1) con-
tained two copies of the NFAT1 RHR, four copies of the FOXP3
FKH domain (i.e., two domain-swapped dimers), and two DNA
molecules. These formed two sets of nearly identical protein-
DNA complexes, each containing one ARRE2 DNA bound by
one NFAT and one domain-swapped FOXP3 dimer. Figure 1A
shows part of the asymmetric unit (NFAT1 and FOXP3 dimer
bound to the upper DNA omitted for clarity). The FOXP3 dimer
bound a different cognate FOXP site on each DNA, thus bridging
two molecules of DNA (see below).
The FOXP3 FKH Domain Has an Optimized
NFAT-Interaction Interface
Each domain-swapped dimer of FOXP3 contains two inter-
twined globular units with the typical structure of the FKH
domain, engaged in intimate contacts with NFAT (Figures 1B
and 2; Figure S1). The details of the protein-protein interaction
between NFAT and FOXP3 (Figures 1C and 1D) are similar to
those in the monomeric NFAT:FOXP2 interface (Stroud et al.,
2006; Wu et al., 2006), supporting our previous analysis
(Wu et al., 2006) and confirming that Thr359, Asn361, His365,480 Immunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc.Glu399, and Glu401 of FOXP3 are located in the center of the
NFAT1:FOXP3 interface and engage in extensive hydrogen
bonding, van der Waals contacts, and electrostatic interactions
with NFAT (Figures 1C and 1D).
Besides the similarities, there are some notable differences in
the binding of FOXP2 and FOXP3 to NFAT. Compared to the
NFAT1:FOXP2 interface, the NFAT:FOXP3 interface is a better
fit and has better chemical complementarity. In particular, the
NFAT1:FOXP3 interface is larger than that of NFAT1:FOXP2,
burying about 1030 A˚2 solvent-accessible surface area as
compared with the 623 A˚2 buried in the NFAT1:FOXP2 interface.
Moreover, superposition of the backbone of the NFAT RHR
N-terminal domain (RHR-N) of the two complexes shows that
Wing1 of the cis-monomer of FOXP3 inserts more deeply into
the CX-E’F-fg groove than Wing1 of FOXP2; as a result, the
C-terminal domains of the NFAT RHR in the two complexes
(RHR-C) show a distinct shift (Figure 1E). At E’F loop and H2 helix
interface, His365 of FOXP3 made extensive van der Waals
contacts with the E’F loop of NFAT (Figure 1D); the correspond-
ing residue in FOXP2 is Ser532, which is too short to interact
with the E’F loop directly (Wu et al., 2006). At the Wing1 and
CX-E’F-fg loop interface, Glu399 and Glu401 form electrostatic
interactions with the basic fg loop of NFAT that contains a string
of positively charged residues, Lys664, Arg665, Lys666, and
Arg667 (Figure 1D). In contrast in FOXP1, FOXP2, and FOXP4,
Glu401 corresponds to a valine, which may not interact with
the basic fg loop of NFAT as favorably (Figure 1C; Wu et al.,
2006). Overall, therefore, our structural analyses indicate that
FOXP3 has a better binding surface for NFAT than FOXP2.
The FKH Domain of FOXP3 Forms
a Domain-Swapped Dimer
A striking feature of the crystal structure is that the FOXP3 FKH
domain exists in the complex as a stable domain-swapped
dimer that bridges two molecules of DNA (Figure S1; Figure 1A).
The domain-swapped dimer of FOXP3 is formed by an exchange
of structural elements: Helix1 (H1), Strand1 (S1), and Helix2 (H2)
of one monomer folded upon Helix3 (H3), Strand2 (S2), and
Strand3 (S3) of the other (Figure 1A; secondary structure labels
follow published conventions; Stroud et al., 2006). The H2
helices are extended, displacing the DNA-binding helix H3
from its own monomer and causing it to be stabilized through
interactions with helices H1 and H2 of the alternate monomer
(Figure 1A).
One monomer (the cis-monomer, red in Figure 1A) bound
to a FOXP site located toward the 30 end of ARRE2:
50-TGGAAAATTTGTTTCA-30 (Figure 1A, site B, underlined;
sequence in bold is the NFAT binding site). The other monomer
(the trans-monomer, blue in Figure 1A) bound another FOXP site
on a separate ARRE2 fragment: 50-TGGAAAATTTGTTTCA-30
(Figure 1A, site A, underlined). The detailed mechanisms of
FOXP3-DNA recognition on site B (Figure S2A) and site A
(Figure S2B) are similar to one another and to those observed in
DNA complexes bound by monomeric FOXP2 (Stroud et al.,
2006). Similarly, the structure of the DNA-binding domain (RHR)
of NFAT and its DNA-binding interactions are similar to those
observed in previously characterized NFAT complexes (Bates
et al., 2008; Chen et al., 1998; Giffin et al., 2003; Jin et al., 2003;
Stroud and Chen, 2003; data not shown).
Figure 1. Overall Structure of the NFAT1:FOXP3:DNA Complex
(A) Arrangement of protein and DNA components in the asymmetric unit. The N-terminal (RHR-N, yellow) and C-terminal (RHR-C, green) domains of NFAT1, and
the cis-monomer (red) and trans-monomer (cyan) of FOXP3 are shown. The sequence of each DNA molecule (stick model) is shown along its orientation in the
crystal. The FOXP3 binding site of the cis-monomer (bottom DNA) and trans-monomer (top DNA) are underlined. The NFAT site is in bold.
(B) Protein-protein interactions between NFAT1 and FOXP3. The NFAT1 (green) and FOXP3 (red and cyan) dimers are shown in space-filling model and DNA in
stick model.
(C) Structural elements of each FOXP3 monomer contribute to protein-protein interactions with NFAT1. Helix H2 of the trans-monomer forms an extensive
interaction interface with the E’F loop of NFAT1. Wing1 of the cis-monomer inserts into a groove formed by the CX loop, the C-terminal stem of the E’F loop, and
the fg loop of NFAT.
(D) Detailed interactions between NFAT and the FOXP3 dimer. Interacting residues are colored and labeled according to their respective proteins.
(E) Superposition of the complex of NFAT1 (yellow), FOXP3 dimer (red and cyan), and DNA (purple) with the complex of NFAT1 (green), FOXP2 monomer
(blue), and DNA (orange). The DNA (orange) in the NFAT1:FOXP2:DNA complex is clearly bent whereas DNA (purple) in the NFAT1:FOXP3:DNA complex is
nearly straight. The NFAT-binding elements (helix H2 and wing W1) of FOXP2 and the FOXP3 dimer are aligned similarly toward NFAT but with a distinct shift.
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Role of Forkhead Dimerization in FOXP3 FunctionDomain swapping in FOXP3 is mediated by an extended
network of hydrophobic residues, including a series of aromatic
residues (Tyr364, Trp366, Phe367, Phe371, Phe373, Phe374,and Trp381) that are highly conserved within the FOX super-
family (Figure 2A, highlighted by blue dots in the alignment of Fig-
ure 2C); two mutations in this interface, F371C and F373A, haveImmunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc. 481
Figure 2. The Dimerization Interface in the
Forkhead Domain of FOXP3
(A) An interaction network of aromatic residues at
the domain-swapped dimer interface present in
both FOXP2 and FOXP3 (see Figure S3, top left).
The red and blue monomers of FOXP3 are shown
with residues colored according to the monomer
to which they belong. The different conformations
of His377 in the two monomers are induced by
different DNA binding interactions at Site A and
Site B (see Figure S2 for details).
(B) An additional hydrophobic core (exclusive to
FOXP3, see Figure S3, top right) that enhances the
stability of the domain-swapped FOXP3 dimer.
(C) Sequence alignment of FOXP family. The
secondary structural elements are shown above
the sequence. Numbering of FOXP2 is shown
above whereas that of FOXP3 is shown below. The
homology is indicated by standard convention
below of the sequence alignment. Residues
involved in DNA binding (magenta), NFAT interac-
tion (green), and domain swapping (blue dots) are
highlighted. The six residues that differ between
FOXP2 andFOXP3 forkheaddomains are indicated
by orange boxes above the sequence alignment.
The blue downward-pointing arrows indicate the
positions of IPEX mutations R347H, F371C, and
F373Athatoccurat thedomain-swap interface, and
the red upward arrows and the pound sign depict
the position of the structure-guided mutations that
we engineered into the interface (see text).
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Role of Forkhead Dimerization in FOXP3 Functionbeen described in IPEX patients (Figure 2C). The stability of
the domain-swapped dimer is enhanced by an additional
hydrophobic interface containing residues Phe340, Leu345,
Trp348, Trp366, and Met370 (Figure 2B). At the center of this
hydrophobic interface are Trp348 and Met370, which corre-
spond to Gln515 and Thr537 in FOXP2, respectively; the IPEX
mutation R347H is also in this interface (Figure 2C). The
sequence differences in the hydrophobic cores of FOXP2 and
FOXP3 may explain the differences in structure and stability of
their respective domain-swapped dimers, as further validated
below.
The FOXP3 FKH domain is likely to form the most stable
domain-swapped dimer in the FOXP family. The sequence of
the 81-residue FKH domains is highly conserved in the FOXP
family, with only six nonhomologous residues (highlighted by
brown bars above the sequence in Figure 2C). Two of these six
residues (His365 and Glu401 of FOXP3) occur at the center of
the NFAT1:FOXP3 interface while another two (Trp348 and
Met370) are located at the core of the domain-swapping
dimer interface, suggesting that the limited variation of surface
residues in the FOXP3 FKH domain confers unique functions
on FOXP3 within the FOXP family. In particular, Trp348 in the
domain-swap interface is conserved across species in FOXP3
but is absent in FOXP1, FOXP2, and FOXP4 (Figure 2C).
Comparison of the FOXP2 (Stroud et al., 2006) and FOXP3
FKH domain structures shows that the domain-swapped
FOXP2 dimer is much less arched than the corresponding
FOXP3 dimer, and thus lacks one of the dimerization interfaces
present in FOXP3 (Figure S3A). Collectively these crystal-struc-
ture data reveal that among the different FOXP family members,482 Immunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc.the FKH domain of FOXP3 is most optimized to form a domain-
swapped dimer and also to interact effectively with NFAT.
The Isolated FKHDomain of FOXP3 Is aDimer in Solution
in the Presence or Absence of DNA
To rule out the possibility that dimerization of the FOXP3 FKH
domain occurred only at the high concentrations required for
crystallization, wemonitored dimer formation by the FKHdomain
in solution (Figure 3A). In the presence of the protein cross-linker
DSS, the FOXP3 FKH domain was predominantly a dimer (Fig-
ure 3A, lane 2). A ternary complex of FOXP3, NFAT, and DNA
was observed only in the presence of DNA containing the
composite ARRE2 element (Figure 3A, lane 4): this complex
was not formed in the absence of DNA (lane 6) or in the presence
of nonspecific DNA (lane 5). These data confirm that the FOXP3
dimer observed in the NFAT:FOXP3:DNA crystal structure is
maintained in solution and that the cooperative NFAT:FOXP3
complex binds to specific DNA sequences (Wu et al., 2006).
Corroborating the cross-linking studies, the FOXP3 FKH
domain eluted as a single peak in size exclusion chromatography
followed by multiangle light scattering (SEC-MALS) analysis;
the molecular weight measured across the entire peak corre-
sponded to a dimer of 26 kDa, suggesting that the FOXP3 dimer
does not exchange into monomer at the lower concentrations
prevailing at the edge of the peak (Figure 3B, left). We also
did not observe any FOXP3 monomer in size exclusion chroma-
tography in dilute solutions (<0.1 mg/ml, data not shown).
Incontrast, FOXP2eluted inSEC-MALSexperimentsasamixture
of monomers and dimers (Stroud et al., 2006; see Figure S3B,
left), and mutation of the critical alanine (Ala539 in FOXP2) to
Figure 3. DSM Mutations Affect Dimeriza-
tion but Do Not Impair DNA Binding by the
Forkhead Domain of FOXP3
(A) Denaturing SDS gel showing formation of
a crosslinked FOXP3 dimer after DSS crosslinking
(lanes 1 and 2) and sequence-dependent cross-
linking of NFAT1 and FOXP3 on the ARRE2 DNA
element (lanes 3–6). The composition of each
reaction is indicated above the lane, and the
concentrations of each component are described
in Experimental Procedures. ns, nonspecific DNA.
(B) SEC-MALS analysis of the forkhead domains of
WT-FOXP3 and the indicated mutants. FOXP3
exists as a stable dimer in solution and elutes as
a single peak (26 kDa, left). The double mutant
(W348Q and M370T FOXP3) elutes as two peaks
of 26 kDa and 13 kDa representing the dimeric and
monomeric forms (middle). The triple DSM mutant
(W348Q, M370T, and A372P) elutes as a single
polydisperse peak (right).
(C) EMSA analysis depicting binding ofWT-FOXP3
and indicated mutants to a DNA probe containing
optimized FOXP3 binding sequences. The muta-
tions do not impair DNA binding by FOXP3.
Immunity
Role of Forkhead Dimerization in FOXP3 Functionproline, conserved in most other FOX proteins, rendered the
FOXP2 FKH domain completely monomeric (Figure 3B, left;
also shown in Figure S3B, right). Thus, the propensity to form
dimers is much stronger in FOXP3 than in FOXP2, and the
FOXP3 FKH domain exists primarily as a stable dimer in solution.
To test whether the unique hydrophobic residues Trp348
and Met370, which are centrally located at the domain-swap
interface, imparted enhanced stability to the FOXP3 dimer,
we replaced Trp348 and Met370 with Gln and Thr, the residues
present at the equivalent positions in FOXP2 (see Figures 2B
and2C). Aspredicted by the crystal structure, these substitutions
destabilized dimerization of the FOXP3 forkhead domain. SEC-
MALS analysis showed that the double-mutant FOXP3 (W348Q
andM370T) eluted as two peaks of 26 kDa and 13 kDa represent-
ing the dimeric and monomeric forms (Figure 3B, middle). An
additional substitution of Ala372 to proline in FOXP3, analogous
to the FOXP2 A539P substitution, which renders FOXP2
completely monomeric (Figure 3B, left; Stroud et al., 2006),
caused the triple mutant (W348Q, M370T, and A372P, hereafter
referred to as FOXP3 domain swap mutant, DSM) to elute as
a single peak on a size exclusion column (Figure 3B, right).
MALS analysis revealed that this peak was polydisperse, sug-
gesting that the triple mutant still undergoes some degree of
dynamic association in solution. Nevertheless, these biochem-
ical analyses corroborate the crystal structure by confirming
that residues Trp348 andMet370 participate in promoting dimer-
ization of the FOXP3 FKH domain.Disruption of the Domain-Swap Interface of FOXP3
Does Not Impair DNA Binding
As predicted by the crystal structure, the DSMmutations did not
affect FOXP3 DNA binding. In electrophoretic mobility shiftassays (EMSA) (Koh et al., 2009), wild-type DN-FOXP3 (amino
acids 182–431) and DN-FOXP3 bearing the domain-swap muta-
tions bound equivalently to the optimized probe (Figure 3C).
Together these data confirm that the domain-swap interface is
not involved in FOXP3 DNA contact.The FKH Domain of FOXP3 Can Bring together Two DNA
Binding Elements in Solution
Domain swapping caused each FOXP3 monomer in the crystal
structure to assume an extended conformation that oriented
the two DNA binding helices (H3) away from each other with
a distance of 48 A˚ from the center of one DNA helix to the other
(Figure 4A). Furthermore, the two DNA-binding H3 helices bound
DNA in antiparallel orientation (Figure 4B), making it unlikely that
the FOXP3 FKH dimer would be able to bind two closely spaced
FOXP3 binding sites. Keeping these structural constraints in
mind, we tested the ability of the FOXP3 FKH domain to engage
two distinct FOXP3-binding sites simultaneously in solution. We
designed a specialized synthetic probe for use in EMSA, con-
taining FOXP3 binding sites at the 50 and 30 ends that were
labeled with the fluorescence energy transfer (FRET) donor-
acceptor pair Cy3 and Cy5, respectively, and were separated
by a flexible 19-base single-stranded DNA linker. The probe
was incubated with increasing concentrations of recombinant
FOXP3 FKH domain in an in-gel FRET assay. Even at the lowest
protein concentrations tested, a clear FRET signal was visible
from the protein-DNA complex (Figure 4C). Although these
data do not distinguish whether the FOXP3 FKH domain bridges
two DNA sites inter- or intramolecularly, they provide clear
evidence that the FOXP3 FKH dimer can simultaneously bind
two distinct FOXP3-binding sites in solution and bring them
into close approximation.Immunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc. 483
Figure 4. The FOXP3 Forkhead Domain Can
Bring together Two FOXP3 DNA Binding
Elements in Solution
The domain-swapped FOXP3dimer (red and cyan)
binds two separate DNA molecules (magenta and
blue, only backbones are shown in ribbons).
(A) View along the DNA axis.
(B) View from the top.
(C) In-Gel FRET analysis: Pseudo-colored image
showing an overlay of the fluorescence of the
Cy3-donor (green) and the fluorescence of the
Cy5-acceptor (red) fluorophores. Labels to the left
indicate the respective DNA/protein species. Note
that unannealed probe (free ss DNA, green) is not
bound by FOXP3 forkhead dimer even at high
protein concentrations and remains unretarded
during electrophoresis.
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Role of Forkhead Dimerization in FOXP3 FunctionMutations that Affect Domain Swapping Differentially
Affect the Expression of FOXP3 Target Genes
To determine whether the triple DSM mutation affected FOXP3
transcriptional activity, we performed microarray-based tran-
scriptional profiling of T cells retrovirally transduced with wild-
type (WT) and DSM FOXP3. Naive T cells, obtained from OT-II
TCR-transgenic mice on a Tcra/ background, were trans-
duced with control (empty) MSCV IRES-Thy1.1 retrovirus or
retroviruses encoding WT or DSM FOXP3; flow cytometric anal-
yses performed 72 hr after retroviral infection confirmed that WT
and mutant FOXP3 were expressed at comparable levels in
primary murine T cells (Figure S4). Successfully transduced
T cells were sorted 72 hr after retroviral infection; RNA was
isolated from a portion of the cells immediately and from another
portion after restimulation for 4 hr with immobilized anti-CD3 and
anti-CD28. The data (average of two experiments) showed that
the transcriptional signature of FOXP3 was largely preserved:
genes induced (red) or repressed (blue) by WT-FOXP3 were
also induced or repressed by the DSM mutant in both resting484 Immunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc.and activated cells (Figure 5A; data not
shown). However, the mutation did
induce a clear off-diagonal shift for a
subset of genes, indicating that for these
genes, the DSM mutations diminished
both the activating and repressive effects
of FOXP3.
To better visualize the impact of the
domain swap mutations, we calculated
a ‘‘DSM index’’ for each gene from the
averaged expression values (WT-DSM/
WT-Empty) (see Supplemental Experi-
mental Procedures). The denominator of
this index is positive for FOXP3-activated
genes, negative for FOXP3-repressed
genes, and 0 for genes whose expres-
sion was unaffected by FOXP3. As the
denominator tends toward zero (i.e., for
geneswhose expression was only slightly
altered by FOXP3), the DSM index tends
to infinity in either direction; to minimize
this problem, we have omitted geneswhose expression was unaltered or only mildly affected by
FOXP3 (Figure 5B, middle section of the graphs).
For both resting (Figure 5B, top) and activated (Figure 5B,
bottom) cells, the ‘‘DSM index’’ highlighted the spectrum of
effects caused by the DSM mutations. A considerable number
of FOXP3-repressed genes were unaffected by the mutations
(indices between 0 and 0.2); this was particularly true for strongly
repressed genes. There were clear exceptions, however; for
instance, FOXP3 modestly repressed Btla, Pde3b, Ptpn22,
and Il2 expression, but repression was eliminated by the
domain-swap mutations (Figure 5B, left half of each panel,
DSM indices > 0.5; Figure S5). Genes activated by FOXP3
showed a more extensive but usually partial effect (indices
around 0.5 for Itgae [CD103], Lag3, and Tnfrsf9 [4-1BB]), indi-
cating that the DSMmutations eliminated50%of the activation
byWT-FOXP3). Activation of some transcripts was unaffected or
only slightly affected by the DSMmutations (Gpr83, Il2ra [CD25],
Ctla4), whereas activation of others was more strongly affected
(Plk2, Blimp1, Ifr4).
Figure 5. Mutations that Disrupt Domain Swapping Differentially Affect Regulation of FOXP3 Target Genes
(A) Gene expression in transfected cells represented as fold change versus fold change (FcFc) plots comparing the effect of transduction of WT- and DSM-Foxp3
relative to mock-transfected cells (resting conditions; all microarray profiles performed in duplicate).
(B) Changes in gene expression as a function of the DSMmutation represented as DSM index (calculated from expression values, (WT-DSM)/(WT-Empty)) versus
fold change in expression obtained upon FOXP3 transduction in resting (top) and activated (bottom) cells.
(C and D) Expression of indicated FOXP3 target genes in WT and DSM transduced T cells as estimated by real-time PCR analysis. Error bars represent the SEM
observed in three independent experiments.
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Role of Forkhead Dimerization in FOXP3 FunctionTo confirm results obtained from the microarray analyses, we
used real-time polymerase chain reaction (PCR) (Figures 5C and
5D) to quantify the expression of genes observed by transcrip-
tional profiling to be either unaffected or dysregulated by the
DSM mutations. For selected genes whose products could be
assessed by flow cytometric analysis, we examined the concor-
dance between mRNA and protein expression (Figure 6A). The
DSM mutations did not substantially alter mRNA or protein
expression of canonical FOXP3 target genes such as Cd25,
Ctla4, Gitr, Entpd1, or Gpr83 (Figures 5C and 6A and data not
shown) but considerably affected the expression of others (Il2,
Cyp11a1, Foxp3 itself, Helios, Prdm1, Tigit, Tnfrsf13b; Figures
5D and 6A). For many genes, the transcriptional changes
induced by WT- and DSM-FOXP3 were only apparent, or only
striking, after activation of the transduced cells (Figures 5B–
5D; Marson et al., 2007).Disruption of the Domain-Swap Interface Eliminates
FOXP3-Mediated Suppressor Functions
We next determined the impact of the DSM mutations on the
suppressor functions of FOXP3. As expected, expression of
WT-FOXP3 conferred potent regulatory activity on transduced
T cells, read out as almost complete suppression of proliferation
of the responder T cells (Figure 6B, top, compare third and fourth
panels). In contrast, cells expressing DSM-FOXP3 exhibited no
discernible regulatory ability, as judged by robust proliferation
of the CFSE-labeled responder T cells (Figure 6B, top, last panel;
quantified for different suppressor:responder ratios in Figure 6B,
bottom). In control experiments, we confirmed that CD4+CD25+
‘‘natural’’ T regulatory cells, freshly isolated ex vivo, displayed
strong suppressive activity (Figure 6B, top, compare first and
second panels). Together the data suggest that domain-swap-
ping contributes critically to the ability of FOXP3 to induceImmunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc. 485
Figure 6. The Domain-Swap Interface Is Required for the Function of FOXP3
(A) Representative flow cytometry plots depicting expression of IL-2 (top) and of CTLA-4, GITR, and CD25 (bottom) in CD4+ T cells transduced with an empty
control vector encoding WT- or DSM-FOXP3. The x axis denotes GFP fluorescence, used as a proxy for FOXP3 expression; GFP expression is controlled by an
IRES element within the bicistronic RNA encoding the FOXP3 coding sequence. The data are representative of three independent experiments. Bar graphs on
right represent percent of IL-2hi cells within the GFP+ population (top). Error bars represent the SEM observed in three independent experiments. The line graphs
depict the fold increase in MFI of CTLA4, CD25, and GITR in transduced cells (top, middle, and bottom, respectively). The data are representative of three
independent experiments.
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coculture system.
To ask whether the effects of the DSM mutation on FOXP3
regulatory function were also apparent in vivo, we used a well-
established mouse model of autoimmune diabetes (Katz et al.,
1995) that we previously employed to demonstrate NFAT:FOXP3
cooperation (Wu et al., 2006). Naive T cells from BDC2.5 T cell
receptor (TCR) transgenic mice, which bear a transgenic TCR
that recognizes chromogranin A expressed by pancreatic b cells
(Stadinski et al., 2010), were differentiated to yield T helper 1 (Th1)
cell-biased T cells. These cells are strongly diabetogenic when
adoptively transferred into neonatal NOD mice, as read out by
rapid onset of diabetes within a week of adoptive transfer.
Cotransfer of CD4+ T cells expressing WT-FOXP3 suppressed
the development of diabetes in the NOD mice as expected
(Peng et al., 2007; Wu et al., 2006). In contrast, cotransfer of
CD4+ T cells expressing mutant DSM-FOXP3 failed to protect
the recipients: hyperglycemia and diabeteswere observedwithin
10 days, as in mice that received only effector cells (Figure 6C).
Nine days after transfer, comparable numbers of transferred cells
expressing DSM-FOXP3 or WT-FOXP3 were detected in the
spleens of recipient mice (Figure S6), indicating that cells ex-
pressing DSM-FOXP3 mutant were not compromised for
survival.
An IPEX Mutation in the FKH Domain Impairs Domain
Swapping and Abrogates FOXP3 Suppressor Function
As described above, three IPEX mutations—F371C, F373A, and
R347H—are found within or near the domain-swap interface of
FOXP3 (Figure 2). Residues F371 and F373 are located at the
interface between the two H2 helices: F373 is buried deeply
within the hydrophobic core, whereas the aromatic ring of
F371 is angled away from the domain-swap interface (Figure 2A).
Consistent with a structural role for F373 in the center of the
domain-swapped interface, the F373A mutant eluted as
a mixture of monomer and dimer peaks on a size exclusion
column (Figure 7B). Thus, the F373A substitution in the FOXP3
FKH domain destabilizes dimer formation; because the SEC-
MALS experiments are performed at highmicromolar concentra-
tions of recombinant proteins, it is likely that the equilibrium
would be further shifted toward the monomer at physiological
concentrations of the F373A protein. In contrast, as predicted
by the structure, the F371Cmutation did not disrupt dimerization
of the FOXP3 FKH domain, as shown by the fact that the mutant
protein eluted as a single peak corresponding to a FOXP3 FKH
dimer (Figure 7B). The dimerization status of the R347H mutant
FKH domain could not be evaluated, because this recombinant
protein was insoluble when expressed in bacteria; however,
FOXP3 bearing both the F347H and F373A mutations bound
as strongly as WT-FOXP3 to DNA (Figure 7B). Based on these(B) Cells expressing the FOXP3 domain swap mutant show decreased suppresso
profile of responder CD4+ T cells cultured with either ex vivo isolated CD4+CD25
(suppressors:responders). Bottom, graph demonstrating relative proliferation of re
different suppressor:respondor ratios. The data are representative of two indepe
(C) Cells transduced with DSM-FOXP3 fail to prevent induction of diabetes in NOD
T cells retrovirally transduced with WT- or DSM-FOXP3 together with Th1 cell effe
kinetics of diabetes induction in recipient mice: cells transduced with WT-FOXP3
with DSM-FOXP3 are ineffective. The data were obtained from three independenfindings, we focused on the biological effect of the F373A IPEX
mutation.
As an independent confirmation of dimerization through the
FOXP3 FKH domain, we assessed dimer formation after limited
cross-linking with BS3, a cross-linking agent with a short spacer
arm (11.4 A˚). For these experiments, we used the same larger
fragment of FOXP3 (aa 182–431) used for the EMSA assays
that contains both the FKH domain and the LZ motif. Into this
fragment, we engineered two known IPEX mutations, DE251 in
the LZ motif (Lopes et al., 2006; Chae et al., 2006) and F373A
in the domain-swap interface. When expressed in a cell-free
system, WT-FOXP3 formed a small amount of an sodium
dodecyl sulfate (SDS)-resistant dimer even in the absence of
cross-linker; addition of BS3 led rapidly, within 30 s, to the
appearance of a50 kDa band corresponding to a FOXP3 dimer
(Figure 7C, panel 2). The DE251 mutation substantially reduced
but did not abrogate dimer formation (Figure 7C, panel 4).
The residual dimer formed by the DE251 mutant involves the
domain-swap interface of the FKH domain, as shown by
the fact that the combination of DE251 and F373A mutations
eliminated formation of both SDS-resistant and cross-linked
dimers (Figure 7C, panel 5). Note that the FKH and LZ interfaces
are distinct: the purified FKH domain of FOXP3 clearly formed
dimers, either as the isolated domain (Figures 3A and 3B, left)
or in the context of a larger fragment bearing theDE251mutation
in the LZ interface.
Together these data show clearly that there are two distinct
and independent dimerization interfaces in FOXP3, the LZ motif
and the domain-swap interface in the FKH domain. Because the
F373A mutation alone did not appreciably diminish dimer forma-
tion, whereas theDE251mutation caused a substantial decrease
(Figure 7C, compare panels 3 and 4), it is likely that the LZmakes
a larger contribution to dimer formation. However, as shown
below, the lower ‘‘affinity’’ FKH dimer interface is essential for
the suppressive function of FOXP3.
We then asked whether the R347H and F373A IPEXmutations
impaired the ability of FOXP3 to induce suppressor activity in ret-
rovirally transduced T cells. T cells expressing WT-FOXP3 effec-
tively suppressed the proliferation of bystander T cells, whereas
FOXP3 proteins bearing the F373A or R347H mutations were
unable to suppress proliferation (Figure 7D; quantified for
different suppressor:responder ratios in Figure 7E). Together
these data suggest strongly that the R347H and F373A IPEX
mutations induce their autoimmune phenotypes in humans by
interfering not with DNA binding (Figure 7A) but rather with the
ability of FOXP3 to form a domain-swapped dimer.
We asked whether we could rescue the defect in suppression
caused by the F373A IPEXmutation in FOXP3 by overexpressing
selected FOXP3 target genes whose expression was affected by
the DSM mutation. T cells were simultaneously infected withr function in vitro. Top, Representative histograms depicting the CFSE dilution
+ T cells or transduced FOXP3-expressing cells (suppressors) at a ratio of 1:2
sponder cells cultured with transduced FOXP3-expressing suppressor cells at
ndent experiments.
recipient mice. Neonatal BDC2.5 TCR transgenic NODmice were injected with
ctors generated from BDC2.5 TCR transgenic mice. The graph represents the
prevent diabetes induction by the effector Th1 cells, whereas cells transduced
t experiments.
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Figure 7. IPEX Mutations that Disrupt Domain Swapping Diminish FOXP3 Regulatory Activity
(A) Forkhead mutations that lie at the domain swap interface do not disrupt DNA binding. EMSA analysis comparing the ability of WT and indicated FOXP3
forkhead mutants to bind DNA.
(B) The F373Amutation at the domain swap interface destabilizes dimer formation by the FOXP3 forkhead domain. SEC-MALS analysis of the forkhead domains
of FOXP3 F371C and F373A shows that the F371C mutant remains a dimer whereas the F373A mutants elutes as a mixture of monomer and dimer.
(C) Denaturing SDS gel of FOXP3 (aa 182–431) before and after brief crosslinkingwith BS3, showing that FOXP3 contains two dimerization interfaces in the leucine
zipper and the forkhead domain. The combination of the DE251 mutation in the leucine zipper and the F373A mutation in the forkhead domain eliminates dimer
formation.
(D) IPEXmutations that destabilize domain swapping abrogate the ability of FOXP3 to induce regulatory functions. Shown is a representative histogram depicting
the CFSE dilution profile of responder cells cultured with transduced WT-FOXP3 or IPEX mutant-expressing cells (suppressors) at a ratio of 1:2
(suppressors:responders).
(E) Graph quantitating relative proliferation of CFSE-labeled responder cells cultured with transduced FOXP3-expressing suppressor cells at different
suppressor:responder ratios. These data are representative of at least two independent experiments.
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either Cyp11a1 or Tigit (with IRES-Gfp). Doubly transduced cells
were sorted based on expression of both markers (Thy1.1 and
GFP), and their suppressive function was compared in
coculture assays with that of cells expressing F373A-FOXP3
and empty Thy1.1 vector. When expressed alone, however,
neither Cyp11a1 nor Tigit rescued the defect in suppressive
activity of F373A-FOXP3 (Figure S7B), consistent with the
hypothesis that suppression depends on the simultaneous
combined actions of several target gene productswhose expres-
sion is disrupted by mutations in the domain-swap interface.
DISCUSSION
In this study, we have solved the crystal structure of a complex of
the FOXP3 FKH domain and the DNA-binding domain of NFAT1
on a composite NFAT:AP-1 (FOXP) DNA element. Our data re-
vealed that the FKH domain of FOXP3 is optimized relative to
that of FOXP2, both for NFAT interaction and for the ability to
form a domain-swapped dimer with the capacity to simulta-
neously engage two distinct molecules of DNA. Notably, despite
their surprisingly limited effects on FOXP3-mediated gene
expression, structure-guided DSM mutations in the domain-
swapped dimer interface of FOXP3 effectively eliminated
FOXP3-mediated suppressor functions, both in culture and in
mouse models of autoimmune disease.
Our studies have important implications for how certain IPEX
mutations in the FKH domain affect the suppressive functions
of regulatory T cells. Based on its location in the FKH domain,
the F373A IPEX mutation was originally proposed to impair
DNA binding by FOXP3 (Bacchetta et al., 2006; Wildin et al.,
2001). Our crystal structure reveals that the F373 residue is
located in the domain-swap interface of FOXP3; as predicted
from this structure, the F373A mutation disrupted dimer forma-
tion by the FKH domain but did not affect DNA binding, and
this disruption of dimer formationwas associatedwith a dramatic
loss of FOXP3-mediated suppressive function. These findings
are consistent with those observed in the clinic: an infant
harboring the F373A mutation presented with a severe form of
IPEX and developed autoimmune insulin-dependent diabetes
mellitus (IDDM) within 2 weeks of life, despite the fact that his
CD4+CD25+ T cells showed normal expression of FOXP3 protein
as well as the cell markers CD25, CTLA4, and GITR (Bacchetta
et al., 2006). For technical reasons associated with inability to
purify the recombinant mutant protein, we were unable to eval-
uate the effect on dimer formation of a second mutation,
R347H, that maps to the domain swap interface; however, this
mutation also eliminated FOXP3 suppressor function while
leaving DNA binding unimpaired. Notably, the severity of autoim-
munity in patients with the F373A and R347Hmutations is similar
to that observed in patients with nonsense or frameshift muta-
tions that result in complete loss of FOXP3 expression, and
both of these missense mutations are associated with neonatal
development of IDDM (Kobayashi et al., 2001; Wildin et al.,
2001, 2002; Bacchetta et al., 2006). A third IPEX mutation in
the domain swap interface, F371C, did not impair dimerization
of the FOXP3 FKH domain, most probably because this residue
does not point inward into the interface; the autoimmunity
observed in patients with the F371C could involve formation ofinappropriate inter- or intramolecular disulphide bonds through
the substituted cysteine. Together, our results highlight the
domain-swap dimer interface as a structural feature of the
FOXP3 forkhead domain, whose disruption underlies human
autoimmune disease.
Our data emphasize that FOXP3 can form multimers in two
distinct modes: through the domain-swap interface in the FKH
domain and through the LZ which mediates FOXP3 homo-oligo-
merization and hetero-oligomerization with FOXP1 (Wang et al.,
2003; Li et al., 2007b). How is dimer formation by the FKH
domain related to oligomerization through the zinc finger (Znf)
and LZ motifs? Modeling studies based on our structural data
suggest that full-length FOXP3 most probably exists as a dimer
of dimers, wherein a pair of FOXP3 molecules form a domain-
swapped dimer through their FKH domains and the two dimers
associate with each other through their Znf-LZ regions. This
oligomerization mechanism is very similar to that of p53, where
a tetramerization domain brings together two pairs of p53
DNA-binding domains, each binding to palindromic site as
a dimer (Chen et al., 2010; Kitayner et al., 2006; Wells et al.,
2008). However, unlike p53, which binds tandem palindromic
sites as a tetramer (Joerger and Fersht, 2008; Wei et al., 2006),
the two DNA binding surfaces on the domain-swapped FOXP3
dimer are located on the opposite faces of a well-folded protein
body, thereby preventing the FOXP3 dimer binding to adjacent
sites. In the crystal structure, the FOXP3 dimer bound two sepa-
rate DNA segments in an antiparallel orientation. In cells, this
interaction may facilitate the assembly of higher-order transcrip-
tion complexes that depend on stereospecific arrangement of
distal DNA elements bridged by the domain-swapped FOXP3
dimer.
It is unlikely that disruption of domain-swapping impairs the
ability of FOXP3 to interact with its known binding partners
NFAT1 (Wu et al., 2006), RUNX1 (Ono et al., 2007), and the
HDAC and 60 kDa Tat-interactive protein (Tip60) complex
(Li et al., 2007a). First, the domain-swap interface and the
NFAT1-binding interface of FOXP3 are physically and function-
ally distinct: CD25, CTLA4, andGITR expression are not affected
by the DSM mutations but are abrogated by disruption of the
NFAT1:FOXP3 interaction (Wu et al., 2006). Second, RUNX1:
FOXP3 interactions diminish FOXP3 expression, not FOXP3-
mediated suppressor function (Bruno et al., 2009; Kitoh et al.,
2009; Klunker et al., 2009; Rudra et al., 2009); because we
induce ectopic expression of FOXP3 by means of retroviruses,
it is unlikely that the defects in suppressor functions induced
by the DSM mutants are due to disruption of RUNX1:FOXP3
interactions. Finally, interaction of FOXP3 with the HDAC and
Tip60 complex has been demonstrated to be essential for
FOXP3-mediated repression of its target genes (Li et al.,
2007a). Because repression of diverse FOXP3 target genes is
unaffected by the DSM mutations, it seems unlikely that these
mutations interfere with formation of the FOXP3:HDAC:Tip60
corepressor complex. An interesting possibility, however, is
that the domain-swapped dimer provides a binding surface for
a yet-unidentified partner of FOXP3.
It is not yet obvious how the limited transcriptional effects of
domain-swap mutations translate into the strong observed
impairment of suppressive activity. The functional impairment
may reflect the combined effect of small changes in theImmunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc. 489
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activity, as observed in Treg cells with 80%–90% decrease in
expression of FOXP3 (Wan and Flavell, 2007), or it may reflect
a requirement for a small number of specific target genes that
have not yet been identified. An equally interesting possibility
is that the domain-swapped FKH dimer recruits novel binding
partners and/or transcriptional regulators to FOXP3-binding
sites in DNA. Future structure-function analyses will expand
our understanding of the mechanism through which FOXP3
induces a suppressor program in T cells and may provide novel
targets for the clinical manipulation of autoimmune and/or
inflammatory diseases and cancer.EXPERIMENTAL PROCEDURES
Detailed methods can be found in Supplemental Experimental Procedures.
Sample Preparation and Crystallization
Human FOXP3 (336-419) and NFAT1 RHR (392-678) were prepared as
described (Stroud et al., 2006; Wu et al., 2006). Data collection, structure
determination, and analyses are described in Supplemental Experimental
Procedures.
Biochemistry
For chemical cross-linking experiments, recombinant proteins were incubated
with DSS for 1 hr. Cross-linked dimers and complexes were visualized by
Commassie staining after separation via denaturing SDS-PAGE. EMSA assays
for FOXP3 DNA binding were performed as described (Koh et al., 2009). For in-
gel FRET analyses, a synthetic probe, containing two double-stranded FOXP3
binding sites separated by a flexible 19-base single-stranded DNA linker and
labeled at the 50 and 30 ends with the FRET-pair Cy3 and Cy5, respectively,
was incubated with increasing concentrations of recombinant FOXP3 fork-
head fragment. DNA-protein complexes were resolved by nondenaturing
PAGE and visualized by Typhoon 8610 variable mode imager. The Cy3 image
(assigned in green in Figure 4C) and the Cy5 (red in Figure 4C) were overlaid.
T Cell Manipulations
T cells from Tcra/ OT-II TCR-transgenic mice were transduced with WT or
DSM FOXP3-IRES-GFP or Thy1.1 retroviruses. IL-2, CTLA-4, and FOXP3
levels were determined by intracellular staining and CD25 and GITR levels
by cell surface staining (Wu et al., 2006). For suppression assays, sorted
Thy1.1+CD4+ T cells expressing WT- or DSM-FOXP3 (suppressors) were
cocultured for 72 hr in 96-well round-bottom plates with 104 mitomycin
C-treated splenocytes, CD3 mAb, and 104 CFSE-labeled CD4+CD25
responder T cells isolated from spleens and lymph nodes of mice by positive
selection with anti-CD4 magnetic beads (Dynal) followed by depletion of
CD25+ cells with anti-CD25 microbeads (Miltenyi). Proliferation of the
responders was monitored by CSFE dye dilution. RNA from sorted Thy1.1+
T cells expressing WT- or DSM-FOXP3 was analyzed by real-time RT-PCR
(StepOne plus thermal cycler, Applied Biosystems). For microarray analysis,
RNA from the sorted cells was extracted, labeled, amplified, and hybridized
to Mouse Gene 1.0 ST Arrays (Affymetrix) (Feuerer et al., 2009).
Induction of Diabetes
CD4+ T cells from BDC2.5/NOD TCR-transgenic mice were activated under
Th1 cell polarizing conditions (Ansel et al., 2004) and infected with MSCV
IRES-Thy1.1 retrovirus, empty or encoding WT- or DSM-FOXP3. Three days
after infection, Thy1.1+ cells were sorted and transferred into neonatal NOD
mice at a 1:2 ratio (0.5 3 105:1 3 105) with untransduced BDC2.5-Th1 cells
(‘‘effector’’ cells). Recipient mice were monitored for diabetes (urinary glucose
more than 300 mg/dl in two consecutive measurements) for 6 weeks. Detailed
methods can be found in Supplemental Experimental Procedures. All experi-
ments were performed in accordance with protocols approved by the Harvard
University Institutional Animal Care and Use Committee and IDI.490 Immunity 34, 479–491, April 22, 2011 ª2011 Elsevier Inc.ACCESSION NUMBERS
The coordinates and structural factors have been deposited in the RCSB
protein database under the accession number 3QRF.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
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